These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1905810)

  • 1. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate.
    Okada H; Inoue Y; Heya T; Ueno H; Ogawa Y; Toguchi H
    Pharm Res; 1991 Jun; 8(6):787-91. PubMed ID: 1905810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate.
    Okada H; Heya T; Ogawa Y; Toguchi H; Shimamoto T
    Pharm Res; 1991 May; 8(5):584-7. PubMed ID: 1907735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals.
    Ogawa Y; Okada H; Heya T; Shimamoto T
    J Pharm Pharmacol; 1989 Jul; 41(7):439-44. PubMed ID: 2570847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay.
    Okada H; Yamazaki I; Yashiki T; Shimamoto T; Mima H
    J Pharm Sci; 1984 Mar; 73(3):298-302. PubMed ID: 6425491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
    Okada H; Heya T; Ogawa Y; Shimamoto T
    J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite.
    Ueno H; Matsuo S
    J Chromatogr; 1991 May; 566(1):57-66. PubMed ID: 1909342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.
    Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H
    Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate.
    Okada H; Doken Y; Ogawa Y
    J Pharm Sci; 1996 Oct; 85(10):1044-8. PubMed ID: 8897268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats.
    Kostanski JW; Dani BA; Schrier B; DeLuca PP
    Pharm Res; 2000 Apr; 17(4):445-50. PubMed ID: 10870989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of LH-RH analogue on pituitary-testicular axis and bladder carcinogenesis of BBN administered male rats].
    Matsuki K; Akaza H; Munakata A; Kameyama S; Aso Y
    Nihon Hinyokika Gakkai Zasshi; 1989 Jul; 80(7):1051-8. PubMed ID: 2514311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats.
    Okada H; Yamazaki I; Sakura Y; Yashiki T; Shimamoto T; Mima H
    J Pharmacobiodyn; 1983 Jul; 6(7):512-22. PubMed ID: 6417315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs.
    Okada H; Doken Y; Ogawa Y; Toguchi H
    Pharm Res; 1994 Aug; 11(8):1199-203. PubMed ID: 7971724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafarelin controlled release injectable: theoretical clinical plasma profiles from multiple dosing and from mixtures of microspheres containing 2 per cent, 4 per cent and 7 per cent nafarelin.
    Burns RA; Vitale K; Sanders LM
    J Microencapsul; 1990; 7(3):397-413. PubMed ID: 2143531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical aspects. Nasal and depot formulations of leuprolide.
    Shimamoto T
    J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.
    Okada H; Yamazaki I; Yashiki T; Mima H
    J Pharm Sci; 1983 Jan; 72(1):75-8. PubMed ID: 6402584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.